ONCOLife Articles
FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy
FDA & EMA | 12 December 2025
Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer
Clinical Trials | 9 December 2025
Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer
Clinical Trials | 11 December 2025
Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer
Clinical Trials | 10 December 2025
Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer
Clinical Trials | 10 December 2025
Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas
ONCOLife | 8 December 2025
Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies
Biotech | 2 December 2025
Blood-Based cfDNA Test Demonstrates Potential for Detecting Lung Cancer in Nonsmokers
ONCOLife
5 December 2025
FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers
FDA & EMA
26 November 2025
FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer
FDA & EMA
24 November 2025
Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer
ONCOLife
5 November 2025
Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer
ONCOLife
6 November 2025
Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer
ONCOLife
3 November 2025
DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer
ONCOLife
4 November 2025
ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment
ONCOLife
4 November 2025
Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer
ONCOLife
24 October 2025
ESMO’s Road Map for Safe and Effective Use of AI-LLMs in Cancer Care: 23 Rules from 20 Experts
AI
3 November 2025
Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer
ONCOLife
21 October 2025
AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%
ONCOLife
18 October 2025
Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma
ONCOLife
20 October 2025
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in the field of oncology. We delve into the stories behind significant clinical research and drug developments, highlight the latest news, and offer exclusive interviews.
